Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330006, China.
Future Oncol. 2013 Mar;9(3):369-76. doi: 10.2217/fon.12.201.
Aptamers are nucleic acid ligands that are generated by molecular evolution to bind with high affinities and specificities to a large variety of targets, which make them attractive tools to be applied in cancer research. In this review, we highlight the recent progress in aptamer-based applications in cancer molecular research such as cancer targeting, biomarker discovery and therapeutics. Aptamers generated from cell-systematic evolution of ligands by exponential enrichment especially contribute to the discovery of novel membrane proteins as cancer biomarkers. Aptamer-nanoparticle conjugation could achieve higher affinity for cancer detection. Aptamer-conjugated nanocarriers deliver drugs to cancer cells with increased specificity and efficacy, as well as reduced toxicity.
适体是通过分子进化产生的核酸配体，能够与多种靶标高亲和力和特异性结合，使其成为应用于癌症研究的有吸引力的工具。在这篇综述中，我们强调了基于适体的应用在癌症分子研究中的最新进展，如癌症靶向、生物标志物发现和治疗。通过指数富集的配体细胞系统进化生成的适体，特别有助于发现新型膜蛋白作为癌症生物标志物。适体-纳米粒子缀合可以提高癌症检测的亲和力。适体偶联的纳米载体将药物递送到癌细胞，提高了特异性和疗效，同时降低了毒性。
